Zobrazeno 1 - 10
of 30
for search: '"785"'
Author/Creator:
Manja Meggendorfer, Susanne Schnittger, Torsten Haferlach, Wolfgang Kern, Claudia Haferlach
Published in:
Blood. 120:3789-3789
Abstract 3789 Introduction: Recently, genes affecting the splicing machinery have been found to be frequently mutated in MDS patients. The U2AF1 gene codes for one of these splicing components, showing two distinct mutational hot spots at amino acids
Published in:
Blood. 132:4849-4849
Background: Newly diagnosed acute myeloid leukemia (ND AML) patients (pts) ineligible for intensive chemotherapy have limited treatment options. Most commonly used low intensity regimens are azacitidine (AZA), decitabine (DEC), or low-dose cytarabine
Author/Creator:
Anja Mottok, Christian Steidl, Randy D. Gascoyne, Maryse M. Power, David Scott, Fong Chun Chan, Alina S. Gerrie, Kerry J. Savage, Sohrab P. Shah, Joseph M. Connors
Published in:
Blood. 124:136-136
Introduction : Classical Hodgkin lymphoma (cHL) is the most common lymphoma affecting individuals under the age of 30. Despite improvements in standard treatment, 25-30% of patients still relapse after first-line treatment with ABVD. Relapsed patient
Author/Creator:
Robert Somerville, Jin Ping, David F. Stroncek, Martin Ongkeko, Amy Wahba, Lipei Shao, Inna Dzekunova, Christina Bailey, Leonard Chen, Sandhya R. Panch, Mame Thioye Sall, Kamille A. West, Opal Reddy, Patrick Danaher, Valeria De Giorgi, Mallikarjuna Rao Gedda
Published in:
Blood
Abstract Introduction Severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) can induce a strong host immune response. Several groups have investigated the course of antibody responses in patients recovering from SARS-CoV-2 infections but little
Author/Creator:
Tammy T. Hshieh, Robert J. Soiffer, Chelsea E. Hawley, Clark DuMontier, Richard Stone, Gregory A. Abel, Jane A. Driver, Tim Jaung, Nupur E. Bahl, Emily S. Magnavita, Lee Mozessohn
Published in:
Blood. 138:4089-4089
Background. Polypharmacy and potentially inappropriate medications (PIMs) are common among older adults with blood cancer and can lead to adverse effects and poor outcomes. Polypharmacy is commonly defined as taking ≥5 or ≥8 medications, dependin
Author/Creator:
Esteban Arrieta-Bolanos, Pietro Crivello, Meilun He, Tao Wang, Shahinaz M. Gadalla, Sophie Paczesny, Steven G.E. Marsh, Stephanie J. Lee, Stephen R. Spellman, Yung-Tsi Bolon, Katharina Fleischhauer
Published in:
Blood. 138:2890-2890
Introduction: Permissive HLA-DPB1 mismatches defined by the T-cell epitope (TCE) model are an established selection criterion for unrelated donors in allogeneic hematopoietic cell transplantation (alloHCT) (Dehn et al. Blood 2019). Based on biologica
Author/Creator:
Colin Burke O'Leary, Megha Shalavadi, Timothy S. Oh, Aryeh Pelcovits, Frederick Lansigan, Jason Lofters, Adam J. Olszewski, Reem Karmali, Elaine Kuhn, Jean L. Koff, Andrew M. Evens, Neil Palmisiano, Melissa Kives, Mingen Liu, Ning C. Dong, Andrea Anampa-Guzman, Tatyana Feldman, Nadia Khan, Stefan K. Barta, Alexey V. Danilov, Jordan Carter, Kerry J. Savage, Shazia Nakohda, Colin Thomas, Carman Tong, Francisco J. Hernandez-Ilizaliturri, Kittika Poonsombudlert, Sabarish Ayyappan, Alexander Hershey, Matthew A. Lunning
Published in:
Blood. 138:50-50
Introduction: While an association between AI diseases and the development of lymphoma (LYM) is known, the impact of AI diseases on patient (pt) outcome across varying LYM subtypes, including the role of immunosuppressive medications (ISM), is not we
Author/Creator:
Christoph Tinchon, Wolfgang R. Sperr, Manuel Drost, Sonja Vallet, Sonja Heibl, Branka Petricevic, Alexander Egle, Hubert Angermann, Gudrun Piringer, Dominik Wolf, Richard Greil, Armin Zebisch, Michael Pfeilstöcker, Heinz Sill, Andreas L. Petzer, Bernd L. Hartmann, Clemens A. Schmitt, Klaus Geissler, Lisa Pleyer, Julian Larcher-Senn, Thomas Melchardt, Margarete Stampfl-Mattesberger, Michael Girschikofsky, Reinhard Stauder, Michael Leisch, Felix Keil, Sigrid Machherndl-Spandl
Published in:
Blood. 138:3387-3387
Background In myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) achievement of complete remission (CR) is a prerequisite for potential cure. In AML, CR/CR with incomplete recovery (CRi) is deemed
Author/Creator:
Oliver Meier, Martynas Aizenas, Francis Nissen, Paul McLaughlin, Cédric Hermans, Thomas W. Burke, Harpal Dhillon, Jamie O'Hara, Sohaib Asghar
Published in:
Blood. 136:33-34
Introduction Severe hemophilia A (SHA) is characterized by spontaneous (non-trauma related) bleeding episodes into the joint space and muscle tissue, leading to progressive joint deterioration and chronic pain. Chronic joint damage is most often asso
Author/Creator:
Jeffrey Y.C. Wong, Thai Cao, Geoffrey Shouse, S.V. Dandapani, Lihua E. Budde, Jekwon Yeh
Published in:
Blood. 136:21-22
Introduction Chimeric Antigen Receptor (CAR) T cell therapy has improved outcomes for relapsed and/or refractory (r/r) B cell lymphomas. Bridging therapy might be needed in some patients for disease control while CAR T product is being produced. Radi